Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Formiga F
- Rubio-Rivas M
- Mora-Luján JM
- Escudero SC
- Martinez RFM
- Mendez-Bailón M
- Campo PD
- Pérez AR
- García-Sánchez FJ
- Alcalá-Pedrajas JN
- Hernández SA
- Milian AH
- Díez AL
- Boixeda R
- Vicente J
- Cortes B
- Pérez CM
- Espartero MEG
- Castro JL
- Suárez SR
- Varona JF
- Gomez-Huelgas R
- Ramos-Rincón JM
- SEMI-COVID-19 SEMI-COVID-19 Network
Grupos
Abstract
Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
© 2021. Società Italiana di Medicina Interna (SIMI).
Datos de la publicación
- ISSN/ISSNe:
- 1828-0447, 1970-9366
- Tipo:
- Article
- Páginas:
- 1-15
- Factor de Impacto:
- 0,861 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
INTERNAL AND EMERGENCY MEDICINE SPRINGER-VERLAG ITALIA SRL
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- Acetylsalicylic acid; COVID-19; Coronavirus; Mortality
Proyectos asociados
SUBREGISTRO PROSPECTIVO, MULTICÉNTRICO Y OBSERVACIONAL DE SEGURIDAD POSTAUTORIZACIÓN PARA CARACTERIZAR EL PERFIL DE SEGURIDAD A LARGO PLAZO DEL USO COMERCIAL DE ELIGLUSTAT (CERDELGA®) EN PACIENTES ADULTOS CON ENFERMEDAD DE GAUCHER.
Investigador Principal: PATRICIA CORRECHER MEDINA
OBS14099 . 2018
MEMORIA PARA EL ESTUDIO DE ESPLENOMEGALIA Y PACIENTES ESPLENECTOMIZADOS NO FILIADOS EN POBLACIÓN INFANTIL Y ADULTA.
Investigador Principal: ISIDRO VITORIA MIÑANA
PREDIGA . 2020
ENSAYO CLINICO ALEATORIZADO PARA EVALUAR LA EFICACIA DE DIFERENTES TRATAMIENTOS EN PACIENTES CON COVID19 QUE REQUIEREN HOSPITALIZACION.
Investigador Principal: MARTA MONTERO ALONSO
PANCOVID . 2020
Cita
Formiga F,Rubio M,Mora JM,Escudero SC,Martinez RFM,Mendez M,Campo PD,Pérez AR,García FJ,Alcalá JN,Hernández SA,Milian AH,Díez AL,Sánchez RG,Boixeda R,Vicente J,Cortes B,Pérez CM,Espartero M,Castro JL,Suárez SR,Varona JF,Gomez R,Ramos JM,SEMI N. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. Intern Emerg Med. 2021. 17. (3):p. 1-15. IF:5,472. (2).